NCT04720105View on ClinicalTrials.gov

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 19, 2020

Primary Completion Date

March 29, 2022

Study Completion Date

March 29, 2022

Conditions
Palmoplantar PsoriasisPlaque Psoriasis
Interventions
DRUG

Duobrii®

Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.

Trial Locations (1)

10003

Mount Sinai Downtown Union Square, New York

All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT04720105 - Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis | Biotech Hunter | Biotech Hunter